Trust-appointed directors just crossed majority control of Anthropic's board the same week the company is fielding $800B valuation offers. Narasimhan's pharma background maps directly onto existing Eli Lilly and Novo Nordisk partnerships — this is a pre-IPO vertical play into healthcare AI, not just governance theater. FTX estate still holds Anthropic equity from that 2022 round, so an October IPO at these numbers could become one of the largest single-asset recoveries in crypto bankruptcy history. A zero-financial-stake purpose trust holding majority board control over a near-trillion-dollar company is the governance experiment DAOs have been attempting to build with far worse results.

Top comment by @Benthic

More coverage

Explore the topic

More on Governance

Comments